Want to see AU:CU6 full AI Analyst Report?

Clarity Pharmaceuticals Ltd. (CU6) Price & Analysis

299 Followers

CU6 Stock Chart & Stats

AU$2.50

-AU$0.09(-4.04%)

At close: Jul 28 4:00 PM EDT

AU$2.50

-AU$0.09(-4.04%)

Day’s Range― - ―

52-Week RangeAU$1.80 - AU$5.87

Previous CloseN/A

Volume1.02M

Average Volume (3M)1.92M

Market Cap

AU$813.32M

Enterprise ValueAU$619.33

Total Cash (Recent Filing)AU$178.25M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.47

Next Earnings

Mar 04, 2027

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding373,081,240

10 Day Avg. Volume1,901,093

30 Day Avg. Volume1,917,191

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)4.23

Price to Sales (P/S)0.00

P/FCF Ratio-8.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$6.79

Price Target Upside171.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.29

Revenue Forecast (FY)AU$7.93M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of reported debt reduces solvency and refinancing risk while preserving financial flexibility. A debt-free structure gives Clarity more capacity to direct available capital toward clinical development and operations without the additional burden of interest payments or lender restrictions.

Growing Equity BasePositive and expanding equity provides a stronger asset base and a buffer against liabilities, supporting the company’s ability to continue its development program. This capital position partly offsets operating weakness by reducing immediate balance-sheet stress and supporting ongoing strategic flexibility.

Historical Revenue ExpansionStrong revenue expansion through 2024 demonstrates that Clarity previously achieved meaningful top-line growth before the later reversal. That history indicates potential commercial traction in the business model, although future progress depends on restoring revenue generation and improving operating performance.

Bears Say

Revenue Collapsed To ZeroThe fall to zero revenue represents a major deterioration in top-line generation and leaves the company without a current recurring revenue base. This weakens earnings visibility, increases reliance on external capital, and makes future value creation dependent on renewed commercial or partnering progress.

Widening Operating LossesWidening operating and net losses show that the current cost base is not being supported by revenue, placing sustained pressure on economic returns. Continued losses can constrain investment flexibility and increase the amount of capital required before the business can reach a self-funding position.

Persistent Cash BurnConsistently negative operating and free cash flow means reported losses are translating into substantial real cash outflows. Accelerating burn raises ongoing funding needs and dilution risk, potentially limiting strategic choices until clinical or commercial activities generate more durable cash inflows.

Clarity Pharmaceuticals Ltd. News

Clarity Pharmaceuticals Sets AGM Date as It Advances Cancer-Focused Radiopharmaceutical Strategy

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an announcement. Clarity Pharmaceuticals Ltd., listed on the ASX under...

36m ago

CU6

Clarity Pharmaceuticals Lifts Revenue but Posts Wider Loss in FY26 Preliminary Results

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an update. Clarity Pharmaceuticals has released its Appendix 4E preliminary...

25d ago

CU6

State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. State Street Corporation and several of its global...

1M ago

CU6

State Street Group Ceases Substantial Holding in Clarity Pharmaceuticals

The latest update is out from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ). State Street Corporation and several of...

2M ago

CU6

Clarity Highlights SAR-bisPSMA Pipeline and Emphasises High-Risk, Early-Stage Profile

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has issued an update. Clarity Pharmaceuticals used the Bioshares Biotech Summit to...

2M ago

CU6

Clarity Posts Strong 67Cu-SAR-bisPSMA Data in SECuRE Prostate Cancer Trial

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an update. Clarity Pharmaceuticals has reported encouraging preliminary safety and...

2M ago

CU6

Clarity Pharmaceuticals Bolsters Cash, Manufacturing and Governance Ahead of Commercial Launch

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. Clarity Pharmaceuticals ended the June 2026 quarter with...

2M ago

CU6

JPMorgan Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. JPMorgan Chase & Co. and its affiliates have...

3M ago

CU6

Vanguard Cuts Stake Below Substantial Holder Threshold in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. Vanguard Group has notified Clarity Pharmaceuticals that it...

3M ago

CU6

Clarity Pharmaceuticals Issues New Shares Following Option Exercise

The latest announcement is out from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ). Clarity Pharmaceuticals has issued 110,000 fully...

3M ago

CU6

CU6 FAQ

What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?

Clarity Pharmaceuticals Ltd. lowest share price was AU$1.80 and its highest was AU$5.87 in the past 12 months.

What is Clarity Pharmaceuticals Ltd.’s market cap?

Clarity Pharmaceuticals Ltd.’s market cap is AU$813.32M.

When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?

Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 164 days.

How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?

Clarity Pharmaceuticals Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.125 earnings per share for the quarter, beating the consensus estimate of -AU$0.152 by AU$0.027.

Is Clarity Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clarity Pharmaceuticals Ltd. pay dividends?

Clarity Pharmaceuticals Ltd. does not currently pay dividends.

What is Clarity Pharmaceuticals Ltd.’s EPS estimate?

Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.14.

How many shares outstanding does Clarity Pharmaceuticals Ltd. have?

Clarity Pharmaceuticals Ltd. has 373,081,240 shares outstanding.

What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?

Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.125 in its last earnings report, beating expectations of -AU$0.152. Following the earnings report the stock price went down -6.4%.

Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:CU6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clarity Pharmaceuticals Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

96.76%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd. (CU6) Earnings & Revenues

Historic Earnings Reports

CU6 Stock 12 Month Forecast

Average Price Target

AU$6.79

▲(171.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"AU$1","3":"AU$3","5":"AU$5","7":"AU$7","9":"AU$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$8.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.793333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$6.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$5.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.7953846153846156,3.260769230769231,3.7261538461538466,4.191538461538462,4.656923076923077,5.122307692307693,5.587692307692308,6.053076923076924,6.518461538461539,6.983846153846154,7.44923076923077,7.914615384615385,{"y":8.38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.6733333333333333,3.0166666666666666,3.3600000000000003,3.7033333333333336,4.046666666666667,4.390000000000001,4.733333333333334,5.076666666666667,5.42,5.763333333333334,6.106666666666667,6.450000000000001,{"y":6.793333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.581538461538462,2.833076923076923,3.0846153846153843,3.336153846153846,3.5876923076923077,3.839230769230769,4.09076923076923,4.342307692307692,4.593846153846154,4.845384615384615,5.096923076923076,5.348461538461538,{"y":5.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >